Insulin resistance is also considered to be a significant pathological characteristic of MS and it has previously been reported that SBP improved insulin resistance as evaluated via glucose tolerance testing (GTT) and insulin dose-response curves (Yanping et al., 2013). Here, INS is linked to myeloid sarcoma.